IndustryCompany release

Biodesix trims 2026 revenue guidance to $101-103M after third-quarter growth falls short of plan

🇺🇸 Biodesix Inc (BDSX) · Thu 05 Nov 2026

The US diagnostics company reported quarterly revenue of $24.0 million, with Diagnostic Testing up 16%, but cited sales force changes, seasonality and delayed development projects.

Biodesix (Nasdaq: BDSX) published its third-quarter 2026 results on 5 November, reporting revenue of $24.0 million, up 10% on the year. Growth fell short of the company's own plan, and it lowered its full-year revenue guidance to a range of $101 million to $103 million.

Diagnostic Testing revenue rose 16%, supported by a 24% increase in test volumes. The company's summary does not give a breakdown of the gap between volume and revenue growth.

Management pointed to three factors behind the shortfall: a smaller sales representative team, stronger seasonality than expected, and delays to projects in its Development Services business.

The company also drew attention to a lung nodule programme framework from CHEST that endorses biomarker testing, naming its Nodify Lung test as an example of such tools. In addition, Biodesix noted new programmes in digital diagnostics and minimal residual disease (MRD) testing. No further detail on these was available in the material reviewed.

What it means for your team

  • Market-access teams tracking lung diagnostics should note the CHEST framework's endorsement of biomarker testing in lung nodule management, which may be cited in coverage and adoption discussions.
  • The guidance cut and the cited delays in Development Services projects may be relevant to sponsors and partners relying on the company's biopharma-facing work for timelines.
  • Details of the new digital diagnostics and MRD programmes were not provided, so regulatory pathways and timelines for these remain unclear.

Company's press release (SEC filing): Biodesix Inc ↗

Article written by VigiEye from the official source (Biodesix Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →